1. Home
  2. BBNX vs LYEL Comparison

BBNX vs LYEL Comparison

Compare BBNX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$12.18

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.70

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
LYEL
Founded
2015
2018
Country
United States
United States
Employees
423
161
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
556.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BBNX
LYEL
Price
$12.18
$23.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$24.00
$30.60
AVG Volume (30 Days)
1.1M
74.3K
Earning Date
04-21-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$34.90
N/A
Revenue Next Year
$34.63
$16,285.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.80
$0.39
52 Week High
$32.71
$45.00

Technical Indicators

Market Signals
Indicator
BBNX
LYEL
Relative Strength Index (RSI) 56.96 55.08
Support Level $9.64 $21.27
Resistance Level $15.53 $27.30
Average True Range (ATR) 0.96 1.71
MACD 0.41 0.43
Stochastic Oscillator 72.79 74.68

Price Performance

Historical Comparison
BBNX
LYEL

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: